Hdac1 and Hdac2 dosage-dependent tumor suppression. (A) Kaplan-Meier tumor-free survival plot of WT, MxCre⁺;Hdac1^L/L and MxCre⁺;Hdac1^L/LHdac2^L/L mice. P value was calculated using a χ² test. (B) CD4/CD8 flow cytometry (top) and Hdac1 and Hdac2 immunohistochemistry (bottom) of tumors from MxCre⁺;Hdac1^L/L and MxCre⁺;Hdac1^L/LHdac2^L/L mice. (C) Global HDAC activity in thymocytes with indicated genotypes relative to WT thymocytes. (D) Kaplan-Meier tumor-free survival plot of mice harboring thymocytes with indicated genotypes. P values were calculated using a χ² test. (E) Representative pictures of Hdac1 and Hdac2 immunohistochemical analysis of lymphomas with indicated genotypes. Magnification: 100×. (F) Global HDAC activity in 4 independent Eμ−Myc and 4 independent Hdac1^Δ/Δ;Hdac2^Δ/+ tumor cell lines. (G) Dose response curves of 4 independent Eμ−Myc and 4 independent Hdac1^Δ/Δ;Hdac2^Δ/+ tumor cell lines treated increasing concentrations of suberoylanilide hydroxamic acid (SAHA). Error bars indicate standard deviations of 3 independent experiments per tumor cell line. WT, wild type.